Publications by authors named "L Yu Danilova"
Seven-day actigraphy was performed within 1 month in 122 community-dwelling adults (mean age 24.40 y, 31 (25.4%) men) in the same city of Tyumen, Russia.
View Article and Find Full Text PDF[Psychopathological disorders at the onset of juvenile parkinsonism in childhood].
Zh Nevrol Psikhiatr Im S S Korsakova
November 2024
Article Synopsis
- The article details a case of a teenage girl diagnosed with juvenile parkinsonism caused by genetic mutations, showcasing the challenges in diagnosing and treating this condition alongside other psychiatric disorders.
- Despite years of psychiatric evaluations and treatments, clear symptoms of parkinsonism only emerged later, complicating the diagnosis.
- It emphasizes the need for a collaborative approach between psychiatrists and neurologists for accurate diagnosis and effective treatment in cases with overlapping symptoms.
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
Background: Brain metastases (BrMs) are a devastating complication of solid tumours. A better understanding of BrMs biology is needed to address their challenging clinical management.
Methods: Immunogenomic and digital spatial analyses were applied to interrogate the peripheral blood and tumour specimens derived from 53 unique patients with BrMs originating from different solid tumours.
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with a poor prognosis. One of the major mechanisms of immune evasion in MCC involves downregulation of major histocompatibility complex class I (MHC-I). Anti-PD-1/programmed death ligand 1 checkpoint inhibitors have revolutionized treatment for MCC, producing objective responses in approximately 50% of patients, and are now the standard of care; however, a substantial proportion of patients either fail to respond or develop resistance to checkpoint inhibitors.
View Article and Find Full Text PDF